ロード中...
Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
The National Comprehensive Cancer Network (NCCN) has recommended Ado-trastuzumab emtansine (T-DM1) as a preferred agent for patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer and prior trastuzumab therapy. Overexpression of HER2 was reported in other canc...
保存先:
| 出版年: | J Res Pharm Pract |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Medknow Publications & Media Pvt Ltd
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5084478/ https://ncbi.nlm.nih.gov/pubmed/27843957 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2279-042X.192458 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|